Khosla Ventures, founded in 2004 and headquartered in Menlo Park, California, is a venture capital firm that provides strategic advice, capital, and support to bold entrepreneurs across various sectors. The firm focuses on early-stage investments in areas such as artificial intelligence, climate technology, sustainability, enterprise solutions, consumer products, fintech, digital health, medical technology, and therapeutics. Khosla Ventures is particularly interested in innovative solutions that address significant socio-economic challenges and enhance productivity, especially for low-income populations and small businesses in emerging markets. The firm embraces experimentation and is open to investing in unconventional and high-risk ventures, often acting as the sole investor in groundbreaking projects. With a commitment to fostering impactful entrepreneurship, Khosla Ventures seeks to create value through technological advancements and creative business models, with a special emphasis on markets in South Asia.
Science is a startup company that develops technologies for a range of serious unmet medical needs.
Tempero Bio
Series B in 2025
Tempero Bio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment and prevention of substance use disorders. The company aims to address the challenges faced by individuals struggling with addiction, providing transformative solutions that help patients overcome treatment obstacles and support their recovery journey. Through its specialized approach, Tempero Bio is dedicated to improving the lives of those affected by substance use disorders and related conditions.
C the Signs
Venture Round in 2025
C the Signs is a cancer prediction system that empowers general practitioners to identify patients at risk of cancer in its early and treatable stages. The platform provides an easy-to-use format for simultaneously checking combinations of signs, symptoms, and risk factors during patient consultations, when decision-making capabilities are most impactful. By analyzing various clinical data points, C the Signs aids physicians in recommending necessary investigations or urgent referrals in under 30 seconds, thereby facilitating timely diagnosis and treatment. The company's mission is to enhance patient outcomes by fast-tracking individuals to appropriate tests or referrals, ultimately aiming to reduce cancer-related mortality rates.
Clear Labs
Series D in 2025
Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dx™ and Clear Safety™, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.
Even
Series A in 2024
Even is a health tech company and healthcare provider that partners directly with the top hospitals in the country to offer you unlimited diagnostics, consultations, and 50 lakh worth of hospitalisations all with one monthly subscription cost.
Neurode
Pre Seed Round in 2024
Neurode is focused on the development of a non-invasive wearable headset aimed at enhancing cognitive performance for individuals with neurological conditions, particularly ADHD. This innovative device employs electrical stimulation to address the imbalances in brain activity commonly associated with ADHD. Alongside the headset, Neurode offers a companion application that monitors users' progress and shares improvements with healthcare professionals. This drug-free approach seeks to alleviate symptoms such as working memory deficits, attention challenges, and impulse control issues, ultimately enabling better management of cognitive performance for users.
Openwater
Venture Round in 2024
Openwater is a San Francisco-based startup founded in 2016 that focuses on developing advanced medical technology aimed at diagnosing and treating diseases at the cellular level. The company has created a wearable device that leverages novel optoelectronic technology to offer high-resolution imaging capabilities, effectively replacing traditional MRI methods. By utilizing LCDs with small pixels, Openwater's device generates holographic images that minimize scattering and achieve MRI-like resolution. This innovation enables physicians to diagnose and treat diseases by targeting individual cells while preserving the surrounding tissue, thereby enhancing the precision and effectiveness of medical interventions.
Even
Venture Round in 2024
Even is a health tech company and healthcare provider that partners directly with the top hospitals in the country to offer you unlimited diagnostics, consultations, and 50 lakh worth of hospitalisations all with one monthly subscription cost.
Q Bio
Venture Round in 2024
Q Bio, founded in 2015 by Jeffrey Kaditz, Dr. Michael Snyder, and Dr. Garry Choy, operates a clinical digital twin platform aimed at assessing patients' medical histories to identify immediate and future health risks. Based in San Carlos, California, the company utilizes whole-body scans to create a digital twin of each patient's physical body, quantifying and digitizing health data. By leveraging simulated human physiology and machine learning, Q Bio's platform can predict potential health risks, enabling healthcare professionals to provide proactive treatment. The interdisciplinary team at Q Bio comprises experts in applied mathematics, computational physics, electrical engineering, genetics, and radiology, supported by prominent venture capital firms.
Sword Health
Secondary Market in 2024
Sword Health is a digital health company focused on revolutionizing physical rehabilitation through its advanced artificial intelligence care platform. The company aims to alleviate pain for billions of people by providing a unique solution that combines the expertise of physical therapy professionals with an interactive AI experience. This platform enables patients to access customized rehabilitation exercises from their homes, allowing them to receive supervised care anytime and anywhere. Sword Health's approach not only enhances patient independence but also offers valuable data to clinical teams and decision-makers, ultimately improving clinical and cost-saving outcomes in the field of physical therapy.
Rubedo Life Sciences
Series A in 2024
Rubedo Life Sciences, Inc. is a biopharmaceutical company based in Sunnyvale, California, focused on developing therapies that target senescent cells responsible for various age-related diseases. Established in 2018, the company utilizes its proprietary ALEMBIC drug discovery platform to create a pipeline of innovative therapeutic candidates. These candidates include novel small molecules designed to selectively address senescent cells, which contribute to the progression of several chronic conditions, including pulmonary, dermatological, oncological, neurodegenerative, and fibrotic diseases. Rubedo's leadership team comprises experienced professionals from the fields of chemistry, technology, and life sciences, bringing a wealth of knowledge in drug development and commercialization.
Nabla Bio
Series A in 2024
Nabla Bio operates an autoreverse platform that facilitates the rapid discovery of novel protein variants with unique properties. By leveraging insights gained from billions of natural proteins, the company engineers these enhanced proteins for both medical and industrial applications. Through extensive experimentation, Nabla Bio develops new medicines and improves nutritional products, allowing clients to conduct complex measurements of protein function and implement innovative solutions in various fields.
Loyal
Series B in 2024
Loyal is a biotechnology company focused on developing veterinary pharmaceuticals aimed at extending the lifespan and improving the health span of dogs. By creating medications that target the aging process, Loyal seeks to delay or prevent the onset of age-related diseases, including cancer, heart disease, and metabolic disorders. The company's innovative approach involves quantifying and regulating the biological processes associated with aging, which helps to mitigate the severity of these ailments. Through its research and product development, Loyal strives to ensure that dogs can enjoy longer, healthier lives, ultimately benefiting both pets and their owners.
Relation Therapeutics
Seed Round in 2024
Relation Therapeutics is a biotechnology company that focuses on humanizing drug discovery and development. It leverages human genetics and clinical omics data and utilizes patient-derived tissue samples with functional genomics interventional experiments to identify, validate, and prosecute therapeutic programs.
Limbic
Series A in 2024
Limbic is a London-based company that specializes in mental healthcare technology. Founded in 2017, it develops a software development kit (SDK) that leverages machine learning to analyze heart rate data collected from wearable devices like the Apple Watch, allowing for the assessment of users' emotional states. Limbic also offers psychological therapies for adults, focusing on improving mental health through innovative solutions. Its platform supports healthcare professionals by providing tools for stress detection and facilitating clinical assessments, thereby enhancing the efficacy of psychological therapy. By combining AI technology with wearable devices, Limbic aims to address the growing challenges in mental health care and improve patient outcomes.
TORTUS AI
Seed Round in 2024
TORTUS AI creates and operates an online tool using artificial intelligence for the healthcare industry. It aims to eliminate human error in medicine through clinician co-working with AI. It provides an AI agent for healthcare, a digital worker that can take over all digital tasks from a clinician such as documentation, requesting tests, access and summarizing patient information. Tortus AI was founded in 2022 and is based in London, England.
Moonwalk Biosciences
Series A in 2024
Moonwalk Biosciences is a genomic medicine startup focused on developing precision epigenetic therapeutics. The company is creating a profiling and engineering technology platform that leverages advanced artificial intelligence to deliver an in-depth understanding of the epigenome in both health and disease. This innovative approach allows healthcare providers to explore new avenues for therapy discovery and facilitates the reprogramming of cells to restore their healthy state. By integrating AI-driven insights, Moonwalk Biosciences aims to transform the landscape of therapeutic development and improve patient outcomes.
Encellin
Series A in 2023
Encellin develops a novel thin-film cell encapsulation device for cell-based therapeutics. It has dedicated experts focused on the investigation and advancement of next-generation therapies. It aims to help patients with chronic diseases, starting with Type 1 diabetes. It was founded in 2016 and is headquartered in San Francisco, California.
Forward
Series E in 2023
Forward is a startup redesigning the way healthcare is delivered using all the technologies healthcare has neglected such as sensors, mobile, and AI. Forward was founded in January 2016 by former executives and engineering leaders from Google and Uber and led by serial entrepreneur Adrian Aoun. Forward is funded by investors and entrepreneurs including First Round Capital, Eric Schmidt (Google/Alphabet chairman), Marc Benioff (Salesforce founder), Joe Lonsdale (Palantir founder), Joshua Kushner (Oscar co-founder), and Garrett Camp (Uber co-founder).
Bold
Series A in 2023
Bold is an at-home digital fitness program designed to help older adults live their strongest, happiest, and healthiest lives. As a member, you’ll enjoy instant access to expert trainers, scientific assessments, and personalized workout plans to help you improve your strength, flexibility, and balance — so you can chase the life you want, at any age.
Rejuvenation Technologies
Seed Round in 2023
Rejuvenation Technologies Inc. is a biotechnology company based in Mountain View, California, focused on developing nucleoside-modified telomerase reverse transcriptase messenger RNA to extend telomeres and promote human health. The company's innovative approach involves delivering a telomere extender that encodes telomerase reverse transcriptase, which transiently boosts telomerase activity in cells. This technology aims to enhance the proliferative capacity of cells, potentially addressing age-related diseases and conditions in various medical fields, including hepatic, pulmonary, and immunology. Additionally, Rejuvenation Technologies offers a range of cell therapies that encompass tissue engineering, cell transplants, skin grafts, immunotherapy, and regenerative medicine. Established in 2016, the company is dedicated to advancing solutions in regenerative health.
SURGE Therapeutics
Series B in 2023
SURGE Therapeutics seeks to dramatically improve cancer patient survival by disrupting cancer immunotherapy is deployed. The company provides an injectable biodegradable hydrogel that allows for the prolonged, localized release of most cancer immunotherapy on the website of surgical tumor resection by focusing the dose at the right place and right time.
SiPhox Health
Seed Round in 2023
SiPhox Health develops advanced diagnostic solutions for both home use and laboratory settings. The company offers an at-home test kit that evaluates 17 blood biomarkers, focusing on areas such as inflammation, hormonal health, metabolic fitness, and cardiovascular health. Their biosensing platform features a handheld device designed to work with disposable cartridges, integrating biochemistry and photonic chip technology. This innovative approach combines integrated photonics, electronics, and microfluidics to deliver sensitive readings of immunoassays and nucleic acids, facilitating point-of-need testing and enhancing the accessibility of diagnostic tools for users.
SiPhox Health
Series A in 2023
SiPhox Health develops advanced diagnostic solutions for both home use and laboratory settings. The company offers an at-home test kit that evaluates 17 blood biomarkers, focusing on areas such as inflammation, hormonal health, metabolic fitness, and cardiovascular health. Their biosensing platform features a handheld device designed to work with disposable cartridges, integrating biochemistry and photonic chip technology. This innovative approach combines integrated photonics, electronics, and microfluidics to deliver sensitive readings of immunoassays and nucleic acids, facilitating point-of-need testing and enhancing the accessibility of diagnostic tools for users.
Eureka Health
Seed Round in 2023
Helping people with chronic conditions mitigate their symptoms.
TORTUS AI
Seed Round in 2023
TORTUS AI creates and operates an online tool using artificial intelligence for the healthcare industry. It aims to eliminate human error in medicine through clinician co-working with AI. It provides an AI agent for healthcare, a digital worker that can take over all digital tasks from a clinician such as documentation, requesting tests, access and summarizing patient information. Tortus AI was founded in 2022 and is based in London, England.
Gather Health
Series A in 2023
Gather Health is an international healthcare technology company dedicated to empowering patients with chronic diseases to enhance their health. The company specializes in mobile and cloud-based healthcare applications that utilize the latest medical and behavioral change research to motivate and educate patients. By connecting physicians, patients, their families, and patient communities, Gather Health aims to provide continuous and holistic care, ultimately improving health outcomes. The rise in chronic diseases, such as obesity and diabetes, has created a demand for better care, which Gather Health addresses by equipping patients and healthcare providers with effective tools for managing these conditions. Their flagship product, the Gather Health Diabetes platform, has been successfully implemented in cities including Mumbai, Ahmedabad, Hyderabad, Chennai, and Bangalore, showing positive health outcomes for patients and increased efficiency for healthcare providers. Headquartered in Hong Kong, with offices in Beijing, New York, and India, Gather Health's team comprises clinicians, health experts, interaction designers, and engineers experienced in global healthcare.
IgGenix
Series B in 2023
IgGenix is a biotechnology company, directly address food and other severe allergies by re-engineering key antibodies involved in the allergic cascade. IgGenix isolates and transforms allergen-specific IgE antibodies into IgG antibodies that are designed to alleviate and possibly prevent the allergic cascade.
Even
Convertible Note in 2022
Even is a health tech company and healthcare provider that partners directly with the top hospitals in the country to offer you unlimited diagnostics, consultations, and 50 lakh worth of hospitalisations all with one monthly subscription cost.
SURGE Therapeutics
Series A in 2022
SURGE Therapeutics seeks to dramatically improve cancer patient survival by disrupting cancer immunotherapy is deployed. The company provides an injectable biodegradable hydrogel that allows for the prolonged, localized release of most cancer immunotherapy on the website of surgical tumor resection by focusing the dose at the right place and right time.
Ochre Bio
Series A in 2022
Ochre Bio Ltd is a biotechnology company focused on developing genomic medicines to improve outcomes for liver transplant patients. Established in 2019 and headquartered in Headington, United Kingdom, the company specializes in rejuvenating donor livers before transplantation, ensuring that more patients in need of a new liver receive one. Utilizing advanced genomic techniques, Ochre Bio identifies and targets over-active genes that contribute to liver diseases. The company tests its novel RNA-based therapies on discarded donor livers kept alive outside the body, allowing for direct evaluation of treatment efficacy. With roots in over 15 years of liver genomics research, Ochre Bio aims to address liver-related conditions and enhance the availability of healthy livers for transplantation.
Proclaim
Series B in 2022
Proclaim is a developer of a oral care platform designed to prevent oral diseases.
Faeth Therapeutics
Series A in 2022
Faeth Therapeutics is a data-driven, evidence-based company that specializes in mechanistic understanding of the way that dietary nutrients influence tumor growth and cancer treatment. It fully focuses on matching specific diets with tumor genotypes and treatment regimens to improve the outcomes of cancer therapy. The company was founded to translate breakthrough discoveries, made by cancer research laboratories, into clinical practice. Its founding team includes some of the industry’s preeminent researchers and clinicians.
CHARM Therapeutics
Series A in 2022
CHARM Therapeutics is focused on developing innovative medicines using advanced 3D deep learning and drug discovery technologies. The company's platform aims to address undruggable disease targets, providing healthcare professionals with effective treatment options for challenging medical conditions. By leveraging cutting-edge technology, CHARM Therapeutics seeks to create transformative therapies that have the potential to significantly improve patient outcomes.
Relation Therapeutics
Seed Round in 2022
Relation Therapeutics is a biotechnology company that focuses on humanizing drug discovery and development. It leverages human genetics and clinical omics data and utilizes patient-derived tissue samples with functional genomics interventional experiments to identify, validate, and prosecute therapeutic programs.
Ultima Genomics
Venture Round in 2022
Ultima Genomics is unleashing the power of genomics at scale. Ultima Genomics drives the scale of genomic information to enable unprecedented advances in biology and improvements in human health. The company was founded in 2016 and is based in Newark, California.
Mirvie
Series B in 2022
Mirvie is a biotech company focused on developing non-invasive tests aimed at improving maternal-fetal health. Founded in 2018 and based in South San Francisco, California, Mirvie offers a medical diagnostic platform that provides actionable insights for mothers and families throughout their pregnancy journey. The company's innovative predictive tests help medical practitioners identify at-risk pregnancies, allowing for timely interventions and enhanced management of pregnancy-related concerns. By prioritizing safety and health, Mirvie seeks to empower families with the information necessary for better pregnancy outcomes.
Turn.bio
Venture Round in 2022
Turn.bio is a biotechnology company focused on developing drugs aimed at reversing aging and age-related diseases. Leveraging its patented mRNA platform technology, known as ERA, the company addresses the effects of aging on the epigenome, thereby restoring optimal gene expression. Turn.bio’s innovative approach enables the body to heal itself by instructing specific cells to combat diseases or repair damaged tissues. The company targets a range of medical indications, including immune-related diseases such as cancer, dermatological conditions, ophthalmology, osteoarthritis, and issues related to the muscular system. Through its advanced delivery platform, eTurna, Turn.bio seeks to enhance the effectiveness of nucleic acid therapeutics in promoting health and longevity.
Faeth Therapeutics
Seed Round in 2022
Faeth Therapeutics is a data-driven, evidence-based company that specializes in mechanistic understanding of the way that dietary nutrients influence tumor growth and cancer treatment. It fully focuses on matching specific diets with tumor genotypes and treatment regimens to improve the outcomes of cancer therapy. The company was founded to translate breakthrough discoveries, made by cancer research laboratories, into clinical practice. Its founding team includes some of the industry’s preeminent researchers and clinicians.
Nabla Bio
Seed Round in 2021
Nabla Bio operates an autoreverse platform that facilitates the rapid discovery of novel protein variants with unique properties. By leveraging insights gained from billions of natural proteins, the company engineers these enhanced proteins for both medical and industrial applications. Through extensive experimentation, Nabla Bio develops new medicines and improves nutritional products, allowing clients to conduct complex measurements of protein function and implement innovative solutions in various fields.
Sword Health
Series D in 2021
Sword Health is a digital health company focused on revolutionizing physical rehabilitation through its advanced artificial intelligence care platform. The company aims to alleviate pain for billions of people by providing a unique solution that combines the expertise of physical therapy professionals with an interactive AI experience. This platform enables patients to access customized rehabilitation exercises from their homes, allowing them to receive supervised care anytime and anywhere. Sword Health's approach not only enhances patient independence but also offers valuable data to clinical teams and decision-makers, ultimately improving clinical and cost-saving outcomes in the field of physical therapy.
Because Market
Series B in 2021
Because Market is a direct-to-consumer personal care company established in 2017, specializing in products tailored for older adults. The company aims to simplify access to essential health and wellness items, including incontinence underwear, pads, skincare, supplements, and walkers. By providing discreet delivery and flexible subscription options, Because Market facilitates the purchasing process for families seeking to support their senior members. With aspirations to become the most trusted brand in this sector, the company has secured over $40 million in funding from prominent venture capital firms, reflecting its commitment to enhancing the lives of older adults and promoting their independence.
Lightship
Series C in 2021
Lightship is a company founded in 2018 that focuses on enhancing access, choice, and equity in clinical trials through decentralized and hybrid clinical services. By leveraging innovations in digital health and technology, Lightship aims to transform the clinical research landscape by improving patient experiences, retention, and trial diversity. The company moves beyond traditional research centers to make clinical studies more accessible, allowing medical research organizations to overcome the barriers and inefficiencies associated with conventional clinical trial models. Its mission centers on placing patients at the forefront, ensuring that clinical research is designed to meet the needs of diverse populations globally.
Loyal
Series A in 2021
Loyal is a biotechnology company focused on developing veterinary pharmaceuticals aimed at extending the lifespan and improving the health span of dogs. By creating medications that target the aging process, Loyal seeks to delay or prevent the onset of age-related diseases, including cancer, heart disease, and metabolic disorders. The company's innovative approach involves quantifying and regulating the biological processes associated with aging, which helps to mitigate the severity of these ailments. Through its research and product development, Loyal strives to ensure that dogs can enjoy longer, healthier lives, ultimately benefiting both pets and their owners.
Vicarious Surgical
Post in 2021
Vicarious Surgical Inc. is a robotics company based in Charlestown, Massachusetts, established in 2014. The company focuses on developing advanced robotic systems that enhance the efficiency of minimally invasive surgical procedures. Its innovative surgical robot combines virtual reality with human-like robotics, allowing for greater precision and control during complex surgeries. Designed for abdominal access, the Vicarious Surgical Robotic System features 3D visualization and operates through a single port, which minimizes invasiveness and promotes faster patient recovery. This compact and portable system can be easily integrated into existing operating rooms, aiming to improve patient outcomes and reduce healthcare costs.
House Rx
Seed Round in 2021
House Rx is a health technology platform focused on improving affordability and patient access to specialty medications.
Checkr
Series E in 2021
Checkr, Inc. is a technology company specializing in the background check industry. Founded in 2014 and headquartered in San Francisco, California, Checkr offers a range of screening services, including criminal record checks, driving checks, and identity verification. The company utilizes advanced technology, including artificial intelligence and machine learning, to deliver faster and more efficient background checks compared to traditional providers. Its platform not only enhances hiring transparency and fairness but also assists businesses in complying with regulations and improving operational efficiency. Checkr serves various sectors, including financial services, healthcare, retail, and technology, providing solutions that cater to the evolving needs of the workforce.
Eight Sleep
Series C in 2021
Eight Sleep, Inc. is a sleep technology company based in New York, founded in 2014. It specializes in the manufacturing and sale of smart mattresses that feature advanced temperature control, allowing users to cool or heat each side of the bed according to their preferences. The products are designed to enhance comfort and support optimal rest, health, and daily functioning by tracking heart rate and other health metrics. In addition to smart mattresses, Eight Sleep offers a range of accessories, including sleep trackers, pillows, organic sheets, foundations, waterproof protectors, blue wave glasses, and gravity blankets. The company primarily sells its products online and is recognized for its innovation in the sleep industry, having been named one of the Most Innovative Companies in Consumer Electronics by Fast Company in 2018.
Encellin
Seed Round in 2021
Encellin develops a novel thin-film cell encapsulation device for cell-based therapeutics. It has dedicated experts focused on the investigation and advancement of next-generation therapies. It aims to help patients with chronic diseases, starting with Type 1 diabetes. It was founded in 2016 and is headquartered in San Francisco, California.
IgGenix
Series A in 2021
IgGenix is a biotechnology company, directly address food and other severe allergies by re-engineering key antibodies involved in the allergic cascade. IgGenix isolates and transforms allergen-specific IgE antibodies into IgG antibodies that are designed to alleviate and possibly prevent the allergic cascade.
Even
Seed Round in 2021
Even is a health tech company and healthcare provider that partners directly with the top hospitals in the country to offer you unlimited diagnostics, consultations, and 50 lakh worth of hospitalisations all with one monthly subscription cost.
Sword Health
Series C in 2021
Sword Health is a digital health company focused on revolutionizing physical rehabilitation through its advanced artificial intelligence care platform. The company aims to alleviate pain for billions of people by providing a unique solution that combines the expertise of physical therapy professionals with an interactive AI experience. This platform enables patients to access customized rehabilitation exercises from their homes, allowing them to receive supervised care anytime and anywhere. Sword Health's approach not only enhances patient independence but also offers valuable data to clinical teams and decision-makers, ultimately improving clinical and cost-saving outcomes in the field of physical therapy.
Ochre Bio
Seed Round in 2021
Ochre Bio Ltd is a biotechnology company focused on developing genomic medicines to improve outcomes for liver transplant patients. Established in 2019 and headquartered in Headington, United Kingdom, the company specializes in rejuvenating donor livers before transplantation, ensuring that more patients in need of a new liver receive one. Utilizing advanced genomic techniques, Ochre Bio identifies and targets over-active genes that contribute to liver diseases. The company tests its novel RNA-based therapies on discarded donor livers kept alive outside the body, allowing for direct evaluation of treatment efficacy. With roots in over 15 years of liver genomics research, Ochre Bio aims to address liver-related conditions and enhance the availability of healthy livers for transplantation.
Ellipsis Health
Series A in 2021
Ellipsis Health, Inc. is a technology company based in San Francisco, California, founded in 2013. It specializes in developing analytics solutions that utilize artificial intelligence to enhance behavioral health assessments by analyzing patient speech and clinical data. The company's platform offers a behavioral biomarker technology that generates clinical-grade evaluations of anxiety and depression severity, as well as sub-clinical assessments of stress. This innovative approach allows healthcare systems to continuously monitor their patient populations for mental health conditions, particularly depression, and facilitates timely support for patients in need. By integrating affective computing into patient and care team interactions, Ellipsis Health aims to create real-time behavioral health vital signs for improved patient outcomes.
Hello Heart
Series C in 2021
Hello Heart is a best in class solution that empowers people to understand and improve their heart health - the #1 cost factor for employers. The program is clinically based and targets people with high blood pressure. Each of our users receives a wireless blood pressure monitor and real-time personalized tips on their smartphone. It is easy to use and helps participants improve their heart health in a fun and engaging way.
Clear Labs
Series C in 2021
Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dx™ and Clear Safety™, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.
Turn.bio
Funding Round in 2021
Turn.bio is a biotechnology company focused on developing drugs aimed at reversing aging and age-related diseases. Leveraging its patented mRNA platform technology, known as ERA, the company addresses the effects of aging on the epigenome, thereby restoring optimal gene expression. Turn.bio’s innovative approach enables the body to heal itself by instructing specific cells to combat diseases or repair damaged tissues. The company targets a range of medical indications, including immune-related diseases such as cancer, dermatological conditions, ophthalmology, osteoarthritis, and issues related to the muscular system. Through its advanced delivery platform, eTurna, Turn.bio seeks to enhance the effectiveness of nucleic acid therapeutics in promoting health and longevity.
Quadrant Eye
Seed Round in 2021
Quadrant Eye is an innovative company focused on transforming the field of online eye care. It has developed a comprehensive eye care platform that provides instant and reliable remote eye exams. This platform facilitates the screening, diagnosis, and management of various low-acuity and chronic eye conditions, such as cataracts, glaucoma, age-related macular degeneration, and diabetic retinopathy. By enabling patients to receive treatment for these conditions from the comfort of their homes, Quadrant Eye aims to enhance access to essential eye care services and improve patient outcomes.
Rightway
Series C in 2021
Rightway is a technology and services company focused on simplifying healthcare for clients and their members. The company develops care navigation and pharmacy benefit management (PBM) solutions aimed at reducing healthcare spending by guiding members toward optimal care and therapies. Rightway's mission centers on using guidance and advocacy to lower costs and improve healthcare outcomes by aligning incentive models and integrating clinicians into the care journey. Its modern care navigation technology offers clinical guidance at a lower cost compared to traditional solutions. Additionally, Rightway's innovative PBM model ensures that every prescription is directed towards the lowest net cost, thereby minimizing expenses for members. The company’s transparent approach to pharmacy benefits is unique in that it incorporates care navigation, enhancing the overall member experience and engagement while addressing total cost-of-care.
Forward
Series D in 2021
Forward is a startup redesigning the way healthcare is delivered using all the technologies healthcare has neglected such as sensors, mobile, and AI. Forward was founded in January 2016 by former executives and engineering leaders from Google and Uber and led by serial entrepreneur Adrian Aoun. Forward is funded by investors and entrepreneurs including First Round Capital, Eric Schmidt (Google/Alphabet chairman), Marc Benioff (Salesforce founder), Joe Lonsdale (Palantir founder), Joshua Kushner (Oscar co-founder), and Garrett Camp (Uber co-founder).
Bold
Seed Round in 2021
Bold is an at-home digital fitness program designed to help older adults live their strongest, happiest, and healthiest lives. As a member, you’ll enjoy instant access to expert trainers, scientific assessments, and personalized workout plans to help you improve your strength, flexibility, and balance — so you can chase the life you want, at any age.
Sword Health
Series B in 2021
Sword Health is a digital health company focused on revolutionizing physical rehabilitation through its advanced artificial intelligence care platform. The company aims to alleviate pain for billions of people by providing a unique solution that combines the expertise of physical therapy professionals with an interactive AI experience. This platform enables patients to access customized rehabilitation exercises from their homes, allowing them to receive supervised care anytime and anywhere. Sword Health's approach not only enhances patient independence but also offers valuable data to clinical teams and decision-makers, ultimately improving clinical and cost-saving outcomes in the field of physical therapy.
Lumiata
Series B in 2021
Lumiata Inc. specializes in predictive health analytics tailored for risk-bearing organizations, including hospital networks and insurance carriers. Founded in 2013 and based in San Mateo, California, the company has developed a medical graph that organizes and analyzes diverse healthcare data, enabling real-time predictive analytics. Its flagship product, The Lumiata Risk Matrix, provides personalized predictions regarding individual health changes, supported by a chain of medical reasoning. By leveraging over 120 million patient records and proprietary clinical knowledge, Lumiata's machine learning tools empower healthcare providers and payers to enhance decision-making, manage costs, and improve patient care. The company serves a range of clients, including payers, population health organizations, and digital health companies, facilitating applications in underwriting and care management while prioritizing member privacy.
Earli
Series A in 2021
Earli is a company focused on developing innovative cancer treatment devices that utilize synthetic biomarkers for early cancer detection. The company's approach involves a novel gene therapy technique known as Synthetic Biopsy, which prompts cancer cells to produce synthetic, non-human biomarkers. These biomarkers can be detected through various means, including blood, urine, or breath, allowing for timely tracking and treatment of cancer. By facilitating the early identification of cancer when it is still homogeneous, Earli aims to significantly enhance survival rates. Their technology not only aids in detection but is also applicable for therapeutic interventions, thereby personalizing treatment and improving patient outcomes.
Curai Health
Series B in 2020
Curai Health is a virtual care company founded in 2017 by Neal Khosla and Xavier Amatriain, headquartered in Palo Alto. The company leverages artificial intelligence to provide chat-based primary care services, aiming to make high-quality and affordable healthcare accessible to everyone, anytime. Curai Health's platform integrates clinicians with advanced AI and machine learning tools to create a learning healthcare system that enhances the efficiency and cost-effectiveness of medical care. By facilitating better communication between patients and healthcare professionals, the platform aids in accurate diagnosis and treatment. Curai Health offers its services directly to consumers and through partnerships with enterprises.
Rubedo Life Sciences
Seed Round in 2020
Rubedo Life Sciences, Inc. is a biopharmaceutical company based in Sunnyvale, California, focused on developing therapies that target senescent cells responsible for various age-related diseases. Established in 2018, the company utilizes its proprietary ALEMBIC drug discovery platform to create a pipeline of innovative therapeutic candidates. These candidates include novel small molecules designed to selectively address senescent cells, which contribute to the progression of several chronic conditions, including pulmonary, dermatological, oncological, neurodegenerative, and fibrotic diseases. Rubedo's leadership team comprises experienced professionals from the fields of chemistry, technology, and life sciences, bringing a wealth of knowledge in drug development and commercialization.
Advanced Chemotherapy Technologies
Series A in 2020
Advanced Chemotherapy Technologies is a healthcare company that is developing breakthrough combination drug-device technologies for treating pancreatic cancer.
Invoy
Series A in 2020
Invoy is a company focused on providing personalized nutrition and wellness services through innovative monitoring medical devices. By utilizing science, data, and artificial intelligence, Invoy's technology captures real-time data on individual metabolism, allowing for tailored nutritional recommendations. The company aims to enhance individual health and weight loss goals by addressing the unique body chemistry of each person. With an emphasis on affordability, Invoy offers breath analyzers for medical applications, enabling users to effectively monitor their health and optimize their wellness journey.
Focal Medical
Series A in 2020
Focal Medical, Inc. is a privately held biopharmaceutical company based in Cary, North Carolina, specializing in the development of innovative drug delivery systems for challenging cancers. The company focuses on creating targeted therapeutic products, with its lead offering designed to deliver gemcitabine directly to the pancreas through non-circulatory pathways, specifically targeting pancreatic cancer. This approach combines iontophoresis with an implantable delivery system, allowing for precise chemotherapy delivery that aims to enhance patient recovery. In addition to pancreatic cancer, Focal Medical is also exploring therapies for other solid tumors and genomic medicine products, underscoring its commitment to advancing treatment options for difficult-to-treat cancers.
SiPhox Health
Seed Round in 2020
SiPhox Health develops advanced diagnostic solutions for both home use and laboratory settings. The company offers an at-home test kit that evaluates 17 blood biomarkers, focusing on areas such as inflammation, hormonal health, metabolic fitness, and cardiovascular health. Their biosensing platform features a handheld device designed to work with disposable cartridges, integrating biochemistry and photonic chip technology. This innovative approach combines integrated photonics, electronics, and microfluidics to deliver sensitive readings of immunoassays and nucleic acids, facilitating point-of-need testing and enhancing the accessibility of diagnostic tools for users.
Vicarious Surgical
Series A in 2020
Vicarious Surgical Inc. is a robotics company based in Charlestown, Massachusetts, established in 2014. The company focuses on developing advanced robotic systems that enhance the efficiency of minimally invasive surgical procedures. Its innovative surgical robot combines virtual reality with human-like robotics, allowing for greater precision and control during complex surgeries. Designed for abdominal access, the Vicarious Surgical Robotic System features 3D visualization and operates through a single port, which minimizes invasiveness and promotes faster patient recovery. This compact and portable system can be easily integrated into existing operating rooms, aiming to improve patient outcomes and reduce healthcare costs.
IgGenix
Series A in 2020
IgGenix is a biotechnology company, directly address food and other severe allergies by re-engineering key antibodies involved in the allergic cascade. IgGenix isolates and transforms allergen-specific IgE antibodies into IgG antibodies that are designed to alleviate and possibly prevent the allergic cascade.
Caption Health
Series B in 2020
Caption Health, Inc. is a technology company that specializes in artificial intelligence-driven software solutions for ultrasound examinations. Founded in 2013 and headquartered in Brisbane, California, the company offers Caption AI, a system designed to assist healthcare providers in acquiring and interpreting ultrasound images. This software provides real-time guidance during exams, automates quality assessments, and facilitates the interpretation of ultrasound results, enabling practitioners to capture high-quality diagnostic images more efficiently. As the adoption of the Caption AI platform grows, Caption Health plans to enhance its technology and expand its clinical capabilities, aiming to integrate its solutions into a wider range of healthcare settings.
Siren Care
Series B in 2020
Siren Care, Inc. is a health technology company based in San Francisco, California, founded in 2015. It specializes in wearable devices designed for diabetic health tracking, particularly through its flagship product, the Siren diabetic socks. These smart socks continuously monitor foot temperature, providing crucial data that can help detect early signs of diabetic ulcers, thereby reducing the risk of amputations. The temperature data is transmitted via an application, allowing healthcare providers to monitor patients effectively and intervene early if necessary. Siren Care aims to enhance healthcare for individuals with chronic diseases by collaborating with both providers and payers to improve patient outcomes in diabetic foot care.
Clear Labs
Venture Round in 2020
Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dx™ and Clear Safety™, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.
HeartVista
Series A in 2020
HeartVista is a medical technology company that provides one-click diagnostic imaging. It brought in machine learning to make the scanning process faster, easier, and more consistent. Its platform leverages existing scanners and contains all of the mri tools needed for a comprehensive cardiac examination, with just one click.
Yes Health
Series A in 2020
Yes Health is an all-mobile diabetes prevention program designed to empower people everywhere to start living healthier, happier lives. Its team is consists of physicians, health coaches and engineers that created a high-engagement program that’s low-cost, easy to follow and successful in preventing the onset of diabetes. People already living with the disease can also use it to successfully manage their symptoms. Yes Health helps people take charge of their health—and have fun doing it—by developing healthy habits that last a lifetime. Its mission is to stop diabetes.
Sword Health
Series A in 2020
Sword Health is a digital health company focused on revolutionizing physical rehabilitation through its advanced artificial intelligence care platform. The company aims to alleviate pain for billions of people by providing a unique solution that combines the expertise of physical therapy professionals with an interactive AI experience. This platform enables patients to access customized rehabilitation exercises from their homes, allowing them to receive supervised care anytime and anywhere. Sword Health's approach not only enhances patient independence but also offers valuable data to clinical teams and decision-makers, ultimately improving clinical and cost-saving outcomes in the field of physical therapy.
Q Bio
Series B in 2020
Q Bio, founded in 2015 by Jeffrey Kaditz, Dr. Michael Snyder, and Dr. Garry Choy, operates a clinical digital twin platform aimed at assessing patients' medical histories to identify immediate and future health risks. Based in San Carlos, California, the company utilizes whole-body scans to create a digital twin of each patient's physical body, quantifying and digitizing health data. By leveraging simulated human physiology and machine learning, Q Bio's platform can predict potential health risks, enabling healthcare professionals to provide proactive treatment. The interdisciplinary team at Q Bio comprises experts in applied mathematics, computational physics, electrical engineering, genetics, and radiology, supported by prominent venture capital firms.
iMerit
Series B in 2020
iMerit is an AI data solutions company that specializes in providing high-quality data for machine learning and artificial intelligence applications across various sectors. The company focuses on data labeling technologies and services, catering to industries such as agricultural AI, autonomous vehicles, commerce, geospatial, government, financial services, and medical AI. Headquartered in San Jose, California, iMerit employs over 5,000 staff members, with a significant representation of women in its workforce. The company operates teams in India, the United States, Bhutan, and Europe, ensuring a diverse and skilled talent pool. Founded by Radha Basu, iMerit serves Fortune 500 companies, helping them achieve optimal results from their algorithms through enriched and accurately labeled data.
Lightship
Series B in 2020
Lightship is a company founded in 2018 that focuses on enhancing access, choice, and equity in clinical trials through decentralized and hybrid clinical services. By leveraging innovations in digital health and technology, Lightship aims to transform the clinical research landscape by improving patient experiences, retention, and trial diversity. The company moves beyond traditional research centers to make clinical studies more accessible, allowing medical research organizations to overcome the barriers and inefficiencies associated with conventional clinical trial models. Its mission centers on placing patients at the forefront, ensuring that clinical research is designed to meet the needs of diverse populations globally.
Eight Sleep
Series C in 2019
Eight Sleep, Inc. is a sleep technology company based in New York, founded in 2014. It specializes in the manufacturing and sale of smart mattresses that feature advanced temperature control, allowing users to cool or heat each side of the bed according to their preferences. The products are designed to enhance comfort and support optimal rest, health, and daily functioning by tracking heart rate and other health metrics. In addition to smart mattresses, Eight Sleep offers a range of accessories, including sleep trackers, pillows, organic sheets, foundations, waterproof protectors, blue wave glasses, and gravity blankets. The company primarily sells its products online and is recognized for its innovation in the sleep industry, having been named one of the Most Innovative Companies in Consumer Electronics by Fast Company in 2018.
Ginger
Series C in 2019
Ginger.io, Inc. is a digital mental health provider that offers a behavioral analytics platform designed to deliver on-demand mental healthcare via mobile devices. Founded in 2010 and headquartered in San Francisco, California, the platform connects users with a team of behavioral health coaches, therapists, and psychiatrists, facilitating personalized care accessible 24/7. Users can collect and analyze both passive and active behavioral data, enabling the identification of health insights and deviations from normal behavior. This service is utilized by a wide range of clients, including researchers, healthcare providers, and millions of employees through partnerships with leading employers and health plans. Ginger's approach focuses on providing immediate support and evidence-based interventions for individuals experiencing mental health challenges such as depression and anxiety.
Encellin
Seed Round in 2019
Encellin develops a novel thin-film cell encapsulation device for cell-based therapeutics. It has dedicated experts focused on the investigation and advancement of next-generation therapies. It aims to help patients with chronic diseases, starting with Type 1 diabetes. It was founded in 2016 and is headquartered in San Francisco, California.
Hello Heart
Series B in 2019
Hello Heart is a best in class solution that empowers people to understand and improve their heart health - the #1 cost factor for employers. The program is clinically based and targets people with high blood pressure. Each of our users receives a wireless blood pressure monitor and real-time personalized tips on their smartphone. It is easy to use and helps participants improve their heart health in a fun and engaging way.
Probably Genetic
Seed Round in 2019
Probably Genetic is dedicated to providing solutions for individuals with rare genetic conditions that are often misdiagnosed as autism spectrum disorder. Recognizing that patients typically endure a lengthy wait of up to seven years for a proper diagnosis, the company aims to alleviate this prolonged uncertainty. They offer educational resources and DNA sequencing tests designed to help individuals and families understand whether there is a genetic basis for their symptoms. By facilitating access to crucial information and testing, Probably Genetic seeks to support those who may otherwise be overlooked by the healthcare system.
Daye
Seed Round in 2019
Daye Ltd is a gynecological health company based in London, United Kingdom, founded in 2018. The company develops, manufactures, and markets female hygiene products under the Your Daye brand, specializing in innovative tampons designed to address period-related issues. Notably, Daye offers CBD-infused tampons that provide a natural alternative to traditional painkillers for managing menstrual cramps. In addition to its tampons, Daye is creating an at-home vaginal microbiome screening kit that allows women to test for infections and microbiome disruptions conveniently. This kit aims to empower women in monitoring their gynecological health, potentially reducing the risk of sexually transmitted infections, gynecological cancers, and complications related to fertility and IVF. Furthermore, Daye plans to launch a comprehensive digital platform focused on gynecological health, aiming to alleviate the challenges women face throughout their health journeys from menstruation to menopause.
Sword Health
Series A in 2019
Sword Health is a digital health company focused on revolutionizing physical rehabilitation through its advanced artificial intelligence care platform. The company aims to alleviate pain for billions of people by providing a unique solution that combines the expertise of physical therapy professionals with an interactive AI experience. This platform enables patients to access customized rehabilitation exercises from their homes, allowing them to receive supervised care anytime and anywhere. Sword Health's approach not only enhances patient independence but also offers valuable data to clinical teams and decision-makers, ultimately improving clinical and cost-saving outcomes in the field of physical therapy.
Because Market
Venture Round in 2019
Because Market is a direct-to-consumer personal care company established in 2017, specializing in products tailored for older adults. The company aims to simplify access to essential health and wellness items, including incontinence underwear, pads, skincare, supplements, and walkers. By providing discreet delivery and flexible subscription options, Because Market facilitates the purchasing process for families seeking to support their senior members. With aspirations to become the most trusted brand in this sector, the company has secured over $40 million in funding from prominent venture capital firms, reflecting its commitment to enhancing the lives of older adults and promoting their independence.
Vicarious Surgical
Series B in 2019
Vicarious Surgical Inc. is a robotics company based in Charlestown, Massachusetts, established in 2014. The company focuses on developing advanced robotic systems that enhance the efficiency of minimally invasive surgical procedures. Its innovative surgical robot combines virtual reality with human-like robotics, allowing for greater precision and control during complex surgeries. Designed for abdominal access, the Vicarious Surgical Robotic System features 3D visualization and operates through a single port, which minimizes invasiveness and promotes faster patient recovery. This compact and portable system can be easily integrated into existing operating rooms, aiming to improve patient outcomes and reduce healthcare costs.
Siren Care
Series A in 2018
Siren Care, Inc. is a health technology company based in San Francisco, California, founded in 2015. It specializes in wearable devices designed for diabetic health tracking, particularly through its flagship product, the Siren diabetic socks. These smart socks continuously monitor foot temperature, providing crucial data that can help detect early signs of diabetic ulcers, thereby reducing the risk of amputations. The temperature data is transmitted via an application, allowing healthcare providers to monitor patients effectively and intervene early if necessary. Siren Care aims to enhance healthcare for individuals with chronic diseases by collaborating with both providers and payers to improve patient outcomes in diabetic foot care.
Clear Labs
Series B in 2018
Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dx™ and Clear Safety™, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.
Openwater
Seed Round in 2018
Openwater is a San Francisco-based startup founded in 2016 that focuses on developing advanced medical technology aimed at diagnosing and treating diseases at the cellular level. The company has created a wearable device that leverages novel optoelectronic technology to offer high-resolution imaging capabilities, effectively replacing traditional MRI methods. By utilizing LCDs with small pixels, Openwater's device generates holographic images that minimize scattering and achieve MRI-like resolution. This innovation enables physicians to diagnose and treat diseases by targeting individual cells while preserving the surrounding tissue, thereby enhancing the precision and effectiveness of medical interventions.
Remedy
Seed Round in 2018
Remedy is a prescriptive chronic care analytics platform employing artificial intelligence to help value-based health systems determine who should get what care, when, how, and by whom to maximize patient health outcomes per dollar spent. We are a design-driven company with core medical AI technology capable of diagnosing disease, catching hidden high-risk diagnoses, and projecting the development of patient’s health into the future. Built around our core AI engine, our first product Remedy Sentinel helps value-based providers identify hidden chronic, co-morbid conditions and intervene by engaging high-risk patients prior to onset. We envision a world where healthcare marries the science of “health” with the art of “care”: scientific, data-driven decision making drives the best outcomes for each individual patient, and frees providers to focus on applying their human touch. Remedy combines novel artificial intelligence algorithms for predictive medical analytics with a healthcare-optimized product development process to give leaders the tools they need to transform their delivery networks and thrive in a value-based care environment. With this approach, Remedy builds a scalable suite of products that, when deployed, learn from experience, and grow into a solution optimized to fit the needs of specific provider groups and the populations they serve. Remedy systematically maximizes the patient health outcome achieved with each dollar spent by using AI to help determine what care is delivered to whom, when it is delivered, where it is delivered, how it is delivered, followed, and supported, and who should deliver it. We not only surface insights, but also build the necessary tools and helps coordinate step-by-step implementation processes to affect real change.
Lumiata
Series B in 2018
Lumiata Inc. specializes in predictive health analytics tailored for risk-bearing organizations, including hospital networks and insurance carriers. Founded in 2013 and based in San Mateo, California, the company has developed a medical graph that organizes and analyzes diverse healthcare data, enabling real-time predictive analytics. Its flagship product, The Lumiata Risk Matrix, provides personalized predictions regarding individual health changes, supported by a chain of medical reasoning. By leveraging over 120 million patient records and proprietary clinical knowledge, Lumiata's machine learning tools empower healthcare providers and payers to enhance decision-making, manage costs, and improve patient care. The company serves a range of clients, including payers, population health organizations, and digital health companies, facilitating applications in underwriting and care management while prioritizing member privacy.
Zebra Medical Vision
Series C in 2018
Zebra Medical Vision Ltd. is a company that develops an imaging analytics platform aimed at enhancing patient care in healthcare institutions. Founded in 2014 and based in Shefayim, Israel, the platform utilizes advanced learning and computer vision algorithms to assist clinicians in identifying patients at risk of various diseases. This technology supports healthcare providers in implementing effective risk management and preventative care strategies. Zebra Medical Vision also supplies tools and datasets for machine-learning researchers, facilitating the rapid development of decision support tools and diagnostic solutions. The company has established strategic partnerships with organizations such as USARAD Holdings and TELUS Ventures, and has secured a total of $52 million in funding from notable investors, including Khosla Ventures and Nvidia. Its AI-driven products are FDA cleared and are utilized in hospitals across multiple regions, including the U.S., Europe, Australia, India, and Latin America, positioning Zebra Medical Vision as a leader in the field of medical imaging and analytics.
Curai Health
Series A in 2018
Curai Health is a virtual care company founded in 2017 by Neal Khosla and Xavier Amatriain, headquartered in Palo Alto. The company leverages artificial intelligence to provide chat-based primary care services, aiming to make high-quality and affordable healthcare accessible to everyone, anytime. Curai Health's platform integrates clinicians with advanced AI and machine learning tools to create a learning healthcare system that enhances the efficiency and cost-effectiveness of medical care. By facilitating better communication between patients and healthcare professionals, the platform aids in accurate diagnosis and treatment. Curai Health offers its services directly to consumers and through partnerships with enterprises.
Vicarious Surgical
Series A in 2018
Vicarious Surgical Inc. is a robotics company based in Charlestown, Massachusetts, established in 2014. The company focuses on developing advanced robotic systems that enhance the efficiency of minimally invasive surgical procedures. Its innovative surgical robot combines virtual reality with human-like robotics, allowing for greater precision and control during complex surgeries. Designed for abdominal access, the Vicarious Surgical Robotic System features 3D visualization and operates through a single port, which minimizes invasiveness and promotes faster patient recovery. This compact and portable system can be easily integrated into existing operating rooms, aiming to improve patient outcomes and reduce healthcare costs.
Siren Care
Seed Round in 2018
Siren Care, Inc. is a health technology company based in San Francisco, California, founded in 2015. It specializes in wearable devices designed for diabetic health tracking, particularly through its flagship product, the Siren diabetic socks. These smart socks continuously monitor foot temperature, providing crucial data that can help detect early signs of diabetic ulcers, thereby reducing the risk of amputations. The temperature data is transmitted via an application, allowing healthcare providers to monitor patients effectively and intervene early if necessary. Siren Care aims to enhance healthcare for individuals with chronic diseases by collaborating with both providers and payers to improve patient outcomes in diabetic foot care.
Eight Sleep
Series B in 2018
Eight Sleep, Inc. is a sleep technology company based in New York, founded in 2014. It specializes in the manufacturing and sale of smart mattresses that feature advanced temperature control, allowing users to cool or heat each side of the bed according to their preferences. The products are designed to enhance comfort and support optimal rest, health, and daily functioning by tracking heart rate and other health metrics. In addition to smart mattresses, Eight Sleep offers a range of accessories, including sleep trackers, pillows, organic sheets, foundations, waterproof protectors, blue wave glasses, and gravity blankets. The company primarily sells its products online and is recognized for its innovation in the sleep industry, having been named one of the Most Innovative Companies in Consumer Electronics by Fast Company in 2018.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.